<DOC>
	<DOCNO>NCT00238316</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . The use letrozole may stop cancer form come back postmenopausal woman increase risk breast cancer due high breast density . PURPOSE : This randomized phase II trial study well letrozole work prevent breast cancer postmenopausal woman increase risk breast cancer due high breast density .</brief_summary>
	<brief_title>Letrozole Preventing Breast Cancer Postmenopausal Women Who Are Increased Risk Breast Cancer Due High Breast Density</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine proportion postmenopausal woman increase risk development recurrence breast cancer , base high breast density ( ≥ grade 4 ) , achieve decrease breast density ≥ 1 grade treatment letrozole 1 year . Secondary - Determine whether decrease breast density grade sustain 1 year patient treat drug . - Correlate plasma estrogen profile ( E1 , E1S , E2 ) breast density grade baseline patient . - Determine percentage patient breast tissue hyperplasia atypical hyperplasia , assess histopathological examination breast tissue biopsy , treatment drug . - Determine change estrogen profile baseline , 1 year , 1 year cessation drug patient . - Compare change predetermine specific parameter safety end 1 year treatment drug baseline evaluation patient . - Determine whether modification predetermine specific parameter safety sustain 1 year cessation treatment drug patient . - Determine general safety 1 year treatment drug patient . - Compare effect drug menopause-specific quality life patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord breast density grade ( 4/6 vs 5/6 v 6/6 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral letrozole daily 1 year absence unacceptable toxicity . - Arm II : Patients receive oral placebo daily 1 year absence unacceptable toxicity . Menopause-specific quality life assess baseline 12 24 month . After completion study treatment , patient follow 6 month 1 year . PROJECTED ACCRUAL : A total 120 patient ( 80 arm I 40 arm II ) accrue study within 12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At increase risk development recurrence breast cancer , define 1 following : Baseline mammogram indicate mammographic density occupy ≥ 25 % ( grade 4/6 , 5/6 , 6/6 ) breast tissue No suspicion breast cancer , unless subsequently rule Prior ductal carcinoma situ ( DCIS ) Untreated disease OR &gt; 6 month since completion adjuvant endocrine therapy Receptor status lesion require Prior invasive breast cancer Breast cancer must surgically remove time original diagnosis evidence metastases No clinical evidence breast cancer Acceptable quality dualenergy xray absorptiometry ( DEXA ) L2L4 posteroanterior ( PA ) spine hip perform within past 6 month Bone mass density Tscore either PA spine hip must ≥ 2.0 SD mean peak bone mass young normal woman Stable chronic leukemia allow Hormone receptor status : Hormone receptornegative , positive , equivocal tumor PATIENT CHARACTERISTICS : Age Postmenopausal Sex Female Menopausal status Postmenopausal , define 1 following : Over 55 year age spontaneous cessation menses ≥ 1 year 55 year age spontaneous cessation menses ≤ 1 year , amenorrheic ( e.g. , spontaneous secondary hysterectomy ) AND folliclestimulating hormone level &gt; 34.4 IU/L Bilateral oophorectomy Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No recent unstable myocardial infarction No prior stroke No high blood pressure No uncontrolled cardiovascular disease Other Other prior malignancy without metastatic disease allow Willing able complete quality life questionnaires either English French No uncontrolled metabolic endocrine disease No malabsorption syndrome PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No concurrent chemotherapy Endocrine therapy See Disease Characteristics At least 3 month since prior concurrent hormone replacement therapy raloxifene At least 6 month since prior tamoxifen No concurrent steroid therapy No concurrent selective estrogenreceptor modulators No concurrent endocrine hormonal therapy Radiotherapy Not specify Surgery See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>breast cancer</keyword>
</DOC>